What Is The Current and Historic Market Size Analysis Of The Allogeneic T Cell Therapies Market?
The allogeneic t cell therapies market has seen considerable growth due to a variety of factors.
• The market size for allogeneic t cell therapies has experienced swift expansion in recent years. It is projected to escalate from $1.16 billion in 2024 to $1.28 billion in 2025, displaying a compound annual growth rate (CAGR) of 10.0%.
The increased growth in the past years is linked to regulatory approvals, the escalating prevalence of cancer, an influx in clinical trials, government support, along with an expanding elderly population.
What Are The Predictions for The Allogeneic T Cell Therapies Market Size?
The allogeneic t cell therapies market is expected to maintain its strong growth trajectory in upcoming years.
• There is a prediction of significant expansion in the allogeneic t cell therapies market within the next several years. The market is estimated to reach a size of $1.85 billion in 2029, growing at a compound annual growth rate (CAGR) of 9.8%.
Factors fostering this projected escalation include broader indications, heightened demand for cell-based immunotherapies, increased awareness of advanced therapies, enhanced healthcare spending, and favorable reimbursement policies. Key trends expected during this forecast period encompass progress in research and development activities, personal medicine, off-the-shelf therapies, expansion of the global market, strategic alliances, and evolution of the regulatory landscape.
Which Factors Are Boosting Growth In The Allogeneic T Cell Therapies Market?
The upsurge in cancer cases is predicted to accelerate the expansion of the allogeneic T cell therapies market. With uncontrolled growth and spread of abnormal cells in the body, cancer is a collection of diseases. The escalation in cancer cases can be attributed to several factors such as extended lifespans, changing lifestyles, environmental exposure, infections, genetic elements, and modifications in reproductive habits. These altogether result in a higher prevalence and detection of the illness. Allogeneic T cell therapies, which involve the infusion of genetically modified donor T cells that identify specific tumor antigens, are utilized for targeting and terminating cancer cells in patients. To illustrate, the National Cancer Institute, a government agency in the US, reported around 18.1 million cancer survivors in the country in May 2024. This number is expected to increase to 22.5 million by 2032. Moreover, the annual new cases of the disease are predicted to hit 29.9 million by 2040, with a corresponding increase in cancer-related deaths reaching an estimated 15.3 million. Consequently, the rise in cancer instances propels the allogeneic T cell therapies market.
What Are The Core Segments Of The Global Allogeneic T Cell Therapies Market?
The allogeneic t cell therapiesmarket covered in this report is segmented –
1) By Product Type: Chimeric Antigen Receptor (CAR) T Cell Therapies, T Cell Receptor (TCR) Therapies, Other Product Types
2) By Antigen Type: CD 19, CD 20, Egfrvlll, GD2, CD22, CD30, CD33, Meso, HER1, Other Antigen Types
3) By Therapeutics Indications: Cancer, Autoimmune Diseases, Infectious Diseases, Others Therapeutics Indications
4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Chimeric Antigen Receptor (CAR) T Cell Therapies: CD19-targeted CAR T Therapies, BCMA-targeted CAR T Therapies, CD22-targeted CAR T Therapies
2) By T Cell Receptor (TCR) Therapies: Neoantigen-targeted TCR Therapies, Viral Antigen-targeted TCR Therapies
3) By Other Product Types: Engineered T Cell Therapies, NK Cell Therapies
Pre-Book The Allogeneic T Cell Therapies Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Allogeneic T Cell Therapies Market Size?
Key players in the allogeneic T cell therapies market are concentrating on the creation of novel chimeric antigen receptor (CAR) T-cell therapy initiatives to increase the effectiveness of treatment and widen the range of therapeutic possibilities. These innovative initiatives refer to advanced strategies aimed at boosting the potency, reach, and method of delivery of CAR T-cell treatments for cancer. For instance, Allogene Therapeutics Inc., a biotechnology firm based in the U.S., initiated CAR T Together in October 2022, with an aim to overcome the hurdles of delivering and accessing CAR T therapies. Its main objective is to simplify the process of enrolling in clinical trials and encourage collaboration amongst oncologists to expedite the progress of allogeneic CAR T therapies. Unlike autologous therapies that utilize the patient's own cells, allogeneic therapies use T cells from healthy donors, which allows for more effective manufacturing procedures.
Who Are the Key Players In The Allogeneic T Cell Therapies Market?
Major companies operating in the allogeneic t cell therapies market are:
• Bristol-Myers Squibb Company
• Novartis AG
• Gilead Sciences Inc.
• Immatics NV
• Sangamo Therapeutics Inc.
• Poseida Therapeutics Inc.
• Fate Therapeutics Inc.
• Atara Biotherapeutics Inc.
• Sorrento Therapeutics Inc.
• Autolus Therapeutics Plc
• MaxCyte Inc.
• Tessa Therapeutics Pte Ltd.
• Cell Medica Inc.
• Enlivex Therapeutics Ltd.
• Cellectis SA
• Adaptimmune Therapeutics Plc
• Medigene AG
• Celyad Oncology SA
• Allogene Therapeutics Inc.
• Bellicum Pharmaceuticals Inc.
What Are The Regional Insights Into The Allogeneic T Cell Therapies Market?
North America was the largest region in the allogeneic T cell therapies market in 2024. The regions covered in the allogeneic T cell therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
